Skip Navigation


Rheumatology Advance Access originally published online on August 2, 2008
Rheumatology 2008 47(10):1590; doi:10.1093/rheumatology/ken326
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/10/1590-a    most recent
ken326v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wailoo, A.
Right arrow Articles by Chilcott, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wailoo, A.
Right arrow Articles by Chilcott, J.
Related Collections
Right arrow Health Economics
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply

A. Wailoo1, N. Bansback2 and J. Chilcott1

1Health Economics and Decision Science, ScHARR, University of Sheffield, Sheffield, UK and 2Centre for Health Evaluation and Outcome Sciences, University of British Columbia, Vancouver, Canada

Correspondence to: A. Wailoo, Health Economics and Decision Science, ScHARR, University of Sheffield, Sheffield, UK. E-mail: a.j.wailoo@sheffield.ac.uk

The first 10% of the full text of this article appears below.

SIR, In our editorial [1], we outlined the considerations National Institute for Health and Clinical Excellence (NICE) has had to make when considering extremely different estimates of cost effectiveness made by sponsors of the three TNF antagonists and an . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?